Where can I learn more about this study?
You can find more information about this study on the websites listed below. When a full report
of the study results is available, it can also be found here.
X www.clinicaltrials.gov Once you are on the website, type “NCT03794544”
into the search box and click “Search”.
X www.clinicaltrialsregister.eu Once you are on the website, click “Home and Search”,
then type “2018-002932-26” in the search box and click “Search”.
X www.AstraZenecaClinicalTrials.com Once you are on the website, type “D9108C00002”
into the search box, and click “Find a Study”.
Full Study Title: A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study
of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with
Resectable, Early-stage (I [> 2 cm] to IIIA N0-1) Non-small Cell Lung Cancer (NeoCOAST)
AstraZeneca Protocol Number: D9108C00002
National Clinical Trials Number: NCT03794544
EudraCT Number: 2018-002932-26
MedImmune LLC sponsored this study and has its headquarters in Gaithersburg, MD, USA.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you!
Clinical study participants belong to a large community of people who take part in
clinical research around the world. They help researchers answer important
health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2022_01_07
12 | Clinical Study Results